NCT04469907 is a Phase 1 clinical trial of AZD9977 in Renal Impairment, sponsored by AstraZeneca.

Who is sponsoring NCT04469907?

NCT04469907 is sponsored by AstraZeneca.

What drugs are being tested in NCT04469907?

Interventions in NCT04469907: AZD9977.

What condition does NCT04469907 study?

NCT04469907 studies Renal Impairment.

Is NCT04469907 still recruiting?

NCT04469907 is currently completed. Last updated 11 March 2022.

Last reviewed 2022-03-11 · How we verify

NCT04469907

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Assess the Pharmacokinetics and Safety of AZD9977 in Participants With Renal Impairment

Completed Phase 1 Last updated 11 March 2022

What this trial tests

Phase 1 trial testing AZD9977 in Renal Impairment in 18 participants. Completed in 28 October 2021.

Timeline

22 June 2020

Primary endpoint
28 October 2021

28 October 2021

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	22 June 2020
Primary completion	28 October 2021
Estimated completion	28 October 2021
Sites	6 locations across United States

Drugs / interventions tested

AZD9977 — full drug profile →

Conditions studied

Renal Impairment — all drugs for Renal Impairment →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 80, any sex, with Renal Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single dose, non-randomized, open-label, parallel group study. The study will be conducted in participants with severe renal impairment and compared with matched participants with normal renal function. The duration of the study for an individual participant from Screening to Follow-up will be approximately 5 weeks.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA).
Sarafidis P, Iatridi F, Ferro C, Alexandrou ME, et al · · 2023 · cited 26× · PMID 37915899 · DOI 10.1093/ckj/sfad139
The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of balcinrenone.
Bhattacharya CS, Ericsson H, Johansson S, Parkinson J, et al · · 2025 · cited 3× · PMID 39962632 · DOI 10.1002/bcp.70017
Population Pharmacokinetic Analysis of Balcinrenone in Healthy Participants and Participants with Heart Failure and Chronic Kidney Disease.
Parkinson J, Åstrand M, Melin J, Ericsson H. · · 2025 · PMID 40965596 · DOI 10.1007/s40262-025-01572-7

Verify or expand the search:

Other trials of AZD9977

Trials testing the same drug.

NCT04595370 — Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Dis · Phase 2 · completed
NCT03843060 — A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Hea · Phase 1 · completed
NCT03801967 — A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Japanese Healthy Participants With Single · Phase 1 · completed
NCT03682497 — Study in HFpEF Patients to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium · Phase 1 · terminated
NCT03435276 — Multiple-ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Healthy Male Subject · Phase 1 · completed

Other recruiting trials for Renal Impairment

Currently open trials in the same condition.

NCT07348237 — A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006) · Phase 1 · recruiting
NCT07315360 — A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function · Phase 1 · recruiting
NCT07217886 — A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls · Phase 1 · recruiting
NCT07154901 — Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD23 · Phase 1 · recruiting
NCT07017933 — Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes · NA · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04469907 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 11 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04469907.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing